Inappropriate suppression of glucagon during OGTT but not during isoglycaemic i.v. glucose infusion contributes to the reduced incretin effect in type 2 diabetes mellitus

Diabetologia

Volumn 50, Issue 4, 2007, Pages 797-805

  Knop, F K ^a,b   Vilsboll T ^a   Madsbad, S ^a   Holst, J J ^b   Krarup, T ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Glucagon; Glucagon like peptide 1; Glucose dependent insulinotropic polypeptide; Incretin effect; Type 2 diabetes mellitus

Indexed keywords

GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; INCRETIN; METFORMIN; SULFONYLUREA;

ADULT; AGED; ARTICLE; BLOOD CHEMISTRY; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; DIET THERAPY; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE INFUSION; GLUCOSE INTOLERANCE; HORMONE RESPONSE; HUMAN; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL; PROTEIN SECRETION;

ADULT; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; GLUCAGON; GLUCAGON-LIKE PEPTIDE 1; GLUCOSE; GLUCOSE TOLERANCE TEST; HUMANS; INSULIN; MALE; MIDDLE AGED; TIME FACTORS;

EID: 33847682160     PISSN: 0012186X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00125-006-0566-z     Document Type: Article

References (43)

1. Muller WA, Faloona GR, Aguilar-Parada E, Unger RH (1970) Abnormal alpha-cell function in diabetes. Response to carbohydrate and protein ingestion. N Engl J Med 283:109-115
2. Reaven GM, Chen YD, Golay A, Swislocki AL, Jaspan JB (1987) Documentation of hyperglucagonemia throughout the day in nonobese and obese patients with noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 64:106-110
3. Unger RH, Orci L (1981) Glucagon and the A cell: physiology and pathophysiology (first of two parts). N Engl J Med 304:1518-1524
4. Unger RH, Orci L (1981) Glucagon and the A cell: physiology and pathophysiology (second of two parts). N Engl J Med 304:1575-1580
5. Baron AD, Schaeffer L, Shragg P, Kolterman OG (1987) Role of hyperglucagonemia in maintenance of increased rates of hepatic glucose output in type-II diabetics. Diabetes 36:274-283
6. Dinneen S, Alzaid A, Turk D, Rizza R (1995) Failure of glucagon suppression contributes to postprandial hyperglycaemia in IDDM. Diabetologia 38:337-343
7. Mitrakou A, Kelley D, Veneman T et al (1990) Contribution of abnormal muscle and liver glucose metabolism to postprandial hyperglycemia in NIDDM. Diabetes 39:1381-1390
8. Shah P, Vella A, Basu A, Basu R, Schwenk WF, Rizza RA (2000) Lack of suppression of glucagon contributes to postprandial hyperglycemia in subjects with type 2 diabetes mellitus. J Clin Endocrinol Metab 85:4053-4059
9. Ipp E (2000) Impaired glucose tolerance: the irrepressible alpha-cell? Diabetes Care 23:569-570
10. Holst JJ (2004) On the physiology of GIP and GLP-1. Horm Metab Res 36:747-754
11. Nauck MA, Kleine N, Orskov C, Holst JJ, Willms B, Creutzfeldt W (1993) Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia 36:741-744
12. Meier JJ, Gallwitz B, Siepmann N et al (2003) Gastric inhibitory polypeptide (GIP) dose-dependently stimulates glucagon secretion in healthy human subjects at euglycaemia. Diabetologia 46:798-801
13. Nauck M, Stockmann F, Ebert R, Creutzfeldt W (1986) Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia 29:46-52
14. Toft-Nielsen MB, Damholt MB, Madsbad S et al (2001) Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients. J Clin Endocrinol Metab 86:3717-3723
15. Vilsboll T, Krarup T, Deacon CF, Madsbad S, Holst JJ (2001) Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients. Diabetes 50:609-613
16. Kjems LL, Holst JJ, Volund A, Madsbad S (2003) The influence of GLP-1 on glucose-stimulated insulin secretion - effects on beta-cell sensitivity in type 2 and nondiabetic subjects. Diabetes 52:380-386
17. Vilsboll T, Krarup T, Madsbad S, Holst JJ (2002) Defective amplification of the late phase insulin response to glucose by GIP in obese type II diabetic patients. Diabetologia 45:1111-1119
18. No authors listed (2002) Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 25 (Suppl 1):S5-S20
19. Alberti KGMM, Zimmet PZ (1998) Definition, diagnosis and classification of diabetes mellitus and its complications part 1: Diagnosis and classification of diabetes mellitus - Provisional report of a WHO consultation. Diabet Med 15:539-553
20. Orskov C, Rabenhoj L, Wettergren A, Kofod H, Holst JJ (1994) Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide-1 in humans. Diabetes 43:535-539
21. Vilsboll T, Krarup T, Sonne J et al (2003) Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus. J Clin Endocrinol Metab 88:2706-2713
22. Krarup T, Holst JJ (1984) The heterogeneity of gastric inhibitory polypeptide in porcine and human gastrointestinal mucosa evaluated with five different antisera. Regul Pept 9:35-46
23. Krarup T, Madsbad S, Moody AJ et al (1983) Diminished immunoreactive gastric inhibitory polypeptide response to a meal in newly diagnosed type I (insulin-dependent) diabetics. J Clin Endocrinol Metab 56:1306-1312
24. Deacon CF, Nauck MA, Meier J, Hucking K, Holst JJ (2000) Degradation of endogenous and exogenous gastric inhibitory polypeptide in healthy and in type 2 diabetic subjects as revealed using a new assay for the intact peptide. J Clin Endocrinol Metab 85:3575-3581
25. Kjems LL, Christiansen E, Volund A, Bergman RN, Madsbad S (2000) Validation of methods for measurement of insulin secretion in humans in vivo. Diabetes 49:580-588
26. Orskov C, Jeppesen J, Madsbad S, Holst JJ (1991) Proglucagon products in plasma of noninsulin-dependent diabetics and nondiabetic controls in the fasting state and after oral glucose and intravenous arginine. J Clin Invest 87:415-423
27. Baldissera FGA, Holst JJ (1984) Glucagon-related peptides in the human gastrointestinal mucosa. Diabetologia 26:223-228
28. Holst JJ, Pedersen JH, Baldissera F, Stadil F (1983) Circulating glucagon after total pancreatectomy in man. Diabetologia 25:396-399
29. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC (1985) Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28:412-419
30. Aronoff SL, Bennett PH, Unger RH (1977) Immunoreactive glucagon (Irg) responses to intravenous glucose in prediabetes and diabetes among pima Indians and normal Caucasians. J Clin Endocrinol Metab 44:968-972
31. Banarer S, McGregor VP, Cryer PE (2002) Intraislet hyperinsulinemia prevents the glucagon response to hypoglycemia despite an intact autonomic response. Diabetes 51:958-965
32. Gerich JE, Langlois M, Noacco C, Karam JH, Forsham PH (1973) Lack of glucagon response to hypoglycemia in diabetes - evidence for an intrinsic pancreatic alpha cell defect. Science 182:171-173
33. Meier JJ, Kjems LL, Veldhuis JD, Lefebvre P, Butler PC (2006) Postprandial suppression of glucagon secretion depends on intact pulsatile insulin secretion - further evidence for the intraislet insulin hypothesis. Diabetes 55:1051-1056
34. Samols E, Stagner JI, Ewart RBL, Marks V (1988) The order of islet microvascular cellular perfusion is β-α-δ in the perfused rat pancreas. J Clin Invest 82:350-353
35. Zhou HR, Tran POT, Yang SL et al (2004) Regulation of alpha-cell function by the beta-cell during hypoglycemia in Wistar rats: the "switch-off" hypothesis. Diabetes 53:1482-1487
36. Nauck MA, Heimesaat MM, Orskov C, Holst JJ, Ebert R, Creutzfeldt W (1993) Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Invest 91:301-307
37. Nauck MA, Kleine N, Orskov C, Holst JJ, Willms B, Creutzfeldt W (1993) Normalization of fasting hyperglycemia by exogenous glucagon-like peptide-1 (7-36 amide) in type-2 (non-insulin-dependent) diabetic-patients. Diabetologia 36:741-744
38. Meier JJ, Nauck MA, Pott A et al (2006) Glucagon-like peptide 2 stimulates glucagon secretion, enhances lipid absorption, and inhibits gastric acid secretion in humans. Gastroenterology 130:44-54
39. Schmidt WE, Siegel EG, Creutzfeldt W (1985) Glucagon-like peptide-1 but not glucagon-like peptide-2 stimulates insulin release from isolated rat pancreatic-islets. Diabetologia 28:704-707
40. Sorensen LB, Flint A, Raben A, Hartmann B, Holst JJ, Astrup A (2003) No effect of physiological concentrations of glucagon-like peptide-2 on appetite and energy intake in normal weight subjects. Int J Obes 27:450-456
41. Bell GI, Santerre RF, Mullenbach GT (1983) Hamster preproglucagon contains the sequence of glucagon and 2 related peptides. Nature 302:716-718
42. Orskov C, Holst JJ, Khuhtsen S, Baldissera FGA, Poulsen SS, Nielsen OV (1986) Glucagon-like peptides Glp-1 and Glp-2, predicted products of the glucagon gene, are secreted separately from pig small-intestine but not pancreas. Endocrinology 119:1467-1475
43. Vilsboll T, Knop FK, Krarup T et al (2003) The pathophysiology of diabetes involves a defective amplification of the late-phase insulin response to glucose by glucose-dependent insulinotropic polypeptide - regardless of etiology and phenotype. J Clin Endocrinol Metab 88:4897-4903